A Randomized, Double-Blind, Split-Face, Clinical Trial of Angiopoietin-1 Derived Peptide Topical Following Fractional Radiofrequency Microneedling.

BACKGROUND

Energy-based devices are commonly used to improve the appearance of aging skin. Treatments can involve long recovery times, marked by pain, erythema, edema, and purpura, which is often a limiting factor in a patient’s willingness to undergo a procedure.

OBJECTIVE

This study evaluated the safety and effectiveness of an Angiopoietin-1 derived QHREDGS peptide (Q-peptide) hydrogel and ointment, in comparison to a peptide-free control, in enhancing healing and patient satisfaction after radiofrequency microneedling (RFMN) treatment.

METHODS

In this Institutional Review Board-approved, randomized, double-blind, split-face study, 8 subjects underwent RFMN. Post-procedure, they applied Q-peptide regimen to one side of their face and a peptide-free control to the other. Post-treatment recovery and skin quality were assessed at 2 ± 1 and 7 ± 1 days post-procedure. Adverse events were monitored.

RESULTS

The Q-peptide regimen was preferred by both clinicians (6-fold) and subjects (5-fold) compared with the control at the first follow-up visit (2 ± 1 days). Subjects were 5-fold more likely to report better-looking skin and 5-fold more likely to report better-feeling skin on the Q-peptide side of the face. Image analysis demonstrated 2-fold decreased presence of edema, erythema, and purpura at 2 ± 1 days post-procedure. Improved skin quality and more rapid recovery were noted with the Q-peptide. By 7 ± 1 days, patients strongly favored Q-peptide, endorsing its continued use and recommending it to others. No adverse events were reported.

CONCLUSION

The Q-peptide regimen was effective and well-tolerated following RFMN treatment, highlighting its potential for skin regeneration and dermatological post-procedure use.